Table 3. Reports of combination chemotherapy for thymoma.
| Regimen | Stage | Patients a | ORR | Reference |
|---|---|---|---|---|
| Anthracycline-containing regimens | ||||
| ADOC (S) | III/IV | 32 | 91% | Fornasiero et al (1990) |
| PAC (G) | IV | 30 | 50% | Loehrer et al (1994) |
| PAC (G) | III | 23 | 70% | Loehrer et al (1997) |
| ADOC (S) | III/IV | 16 | 81% | Berruti et al (1999) |
| PAC (G) | III/IV | 22 | 77% | Kim et al (2004) |
| PAE (S) | III/IV | 30 | 73% | Lucchi et al (2006) |
| CAMP (S) | III/IV | 14 | 93% | Yokoi et al (2007) |
| CODE (G) | IV | 27 | 59% | Current study |
| Non-anthracycline-containing regimens | ||||
| PE (G) | III/IV | 16 | 56% | Giaccone et al (1996) |
| VIP (G) | III/IV | 20 | 35% | Loehrer et al (1997) |
| CP (G) | III/IV | 23 | 35% | Lemma et al (2008) |
Abbreviations: ADOC=doxorubicin, cisplatin, vincristine, cyclophosphamide; CAMP=cisplatin, doxorubicin, methylpredonisolone; CODE=cisplatin, vincristine, doxorubicin, etoposide; CP=carboplatin, paclitaxel; G=prospective multicenter group trial; ORR=overall response rate; PAC=cisplatin, doxorubicin, cyclophosphamide; PAE=cisplatin, epidoxorubicin, etoposide; PE=cisplatin, etoposide; S=single-center experience; VIP=etoposide, ifosfamide, cisplatin.
a
Number of assessable patients.